|
|
Volumn 97, Issue 4, 2005, Pages 255-256
|
|
Complementary, alternative therapies should face rigorous testing, IOM concludes
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
HERBACEOUS AGENT;
ALTERNATIVE MEDICINE;
CANCER PATIENT;
CANCER THERAPY;
CASE CONTROL STUDY;
CLINICAL OBSERVATION;
CLINICAL TRIAL;
COHORT ANALYSIS;
DIET SUPPLEMENTATION;
DRUG EFFICACY;
DRUG LABELING;
DRUG SAFETY;
HEALTH CARE COST;
HEALTH CARE QUALITY;
HERBAL MEDICINE;
HUMAN;
INDIVIDUALIZATION;
NOTE;
OUTCOMES RESEARCH;
PRIORITY JOURNAL;
PUBLIC HEALTH SERVICE;
RELIABILITY;
RISK BENEFIT ANALYSIS;
STANDARDIZATION;
STATISTICAL ANALYSIS;
TREATMENT INDICATION;
TREATMENT PLANNING;
ARTICLE;
CONTROLLED CLINICAL TRIAL;
ECONOMICS;
RANDOMIZED CONTROLLED TRIAL;
STANDARD;
UNITED STATES;
COMPLEMENTARY THERAPIES;
HUMANS;
RANDOMIZED CONTROLLED TRIALS;
UNITED STATES;
|
|
EID: 13844312815
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/97.4.255 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|